Browsing Tag
NMPA
17 posts
Zydus Lifesciences (NSE: ZYDUSLIFE) wins NMPA approval for Desidustat in China, unlocking access to 120 million CKD patients
Zydus Lifesciences' novel oral drug Desidustat receives China NMPA approval for CKD anaemia, unlocking a market of 120 million patients. Read the strategic analysis.
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after positive Phase III trial
Akeso files gumokimab for NMPA review in ankylosing spondylitis. Find out how this move expands its autoimmune pipeline beyond oncology.
BeOne Medicines’ sonrotoclax trial hits primary endpoint in mantle cell lymphoma patients
BeOne Medicines’ sonrotoclax met its primary endpoint in mantle cell lymphoma, with positive Phase 1/2 trial results. Find out what this means for patients.
BioCity’s SC0062 secures second breakthrough therapy designation in China for diabetic kidney disease
BioCity Biopharma’s ETA-selective SC0062 earns second Breakthrough Therapy Designation in China for diabetic kidney disease, reinforcing its CKD potential.
Lupin signs China licensing deal for COPD drug Tiotropium DPI with Sino Universal Pharmaceuticals
Lupin enters China’s COPD market with a Tiotropium DPI licensing deal. Learn how this move shapes its global respiratory growth strategy.
CirCode Biomed’s HM2002 gets FDA green light: World’s first circular RNA drug to enter U.S. clinical trials for heart disease
CirCode’s HM2002 becomes the first circular RNA drug cleared by the FDA for clinical trials in ischemic heart disease—setting a precedent in RNA therapeutics.
Hutchmed secures priority review in China for ORPATHYS and TAGRISSO combination therapy
Hutchmed (China) Limited has achieved a significant milestone with the acceptance of its New Drug Application (NDA) by…
Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical…
GSK seeks to extend shingles vaccine Shingrix to younger at-risk adults in China
GSK plc (LSE/NYSE: GSK) has reached a pivotal milestone in the prevention of shingles (herpes zoster) in China,…
Avistone Biotechnology receives NMPA approval for Vebreltinib in China
Avistone Biotechnology Co. Ltd., a precision oncology therapeutics company, has announced the conditional approval from the National Medical…